Constellation Pharmaceuticals, Inc. (CNST)
(Delayed Data from NSDQ)
$13.30 USD
+0.45 (3.50%)
Updated May 3, 2019 04:00 PM ET
After-Market: $13.15 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[CNST]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Industry: Medical - Biomedical and Genetics
Clinical Updates Expected for MANIFEST and CPI-0209 Programs in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
MANIFEST Updates in 2021 Will Provide More Clarity; Reit Buy and $75 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
MANIFEST Continues to be a Shining Star at the ASH 2020 Annual Meeting; Reit Buy and $75 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
The Stars Are Aligning for CNST at ASH 2020; Reit Buy and $75 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Looking Beyond Myelofibrosis; Reit Buy and $75 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
A Closer Look at CPI-0610?s Hematologic Effects; Reit Buy and $75 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
EHA Abstract Continues to Support Clinical Path in Frontline Myelofibrosis; Reit Buy and $75PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Awaiting Regulatory Clarity and Looking Ahead to a Data-Rich 2020; Reit Buy and $50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Our Thoughts Following MANIFEST Data Update at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Going Straight to the First-Line; Reit Buy and Raising PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Steady Progress With Multiple Catalysts in the Near Term; Reit Buy and $18 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
KOL Breakfast at ASCO Highlights CPI-0610?s Potential in Myelofibrosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Upcoming MANIFEST Data Readout Could Be Highly Validating
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
New Epigenetic Approaches to Prostate Cancer from AACR
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
ProSTAR AACR Update Continues to Support CPI-1205?s Potential in mCRPC
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Still an Underappreciated Story While Upcoming Data Catalysts Could Be Value-Inflecting
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
MANIFEST Data Update Continues to Support CPI-0610?s Disease-Modifying Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Maximizing the Potential of Targeting Epigenetics in Cancer; Initiate With Buy and $18 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
|